UNICHEMLAB

March 20 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• COMPLETES PHASE I CAPACITY EXPANSION OF API PLANT

Source text: ID:nBSE9rGmJY

Further company coverage: UNLB.NS

(([email protected];;))

** Shares of Unichem Laboratories UNLB.NS rise 5.6% to 639 rupees

** Pharmaceutical co to sell 3.4 acres of land and old construction building area at Prabhat Estate in Mumbai for 2.79 bln rupees ($31.9 mln) to Macrotech Developers MACE.NS

** Stock set to snap five-session losing streak

** UNLB down ~14.2% in 2025 vs 83.2% gains in 2024

($1 = 87.3480 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

Feb 6 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABS DEC-QUARTER CONSOL PAT 578.5 MILLION RUPEES

• UNICHEM LABS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.33 BILLION RUPEES

Source text: ID:nnAPN2N3ISB

Further company coverage: UNLB.NS

(([email protected];))

Jan 24 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• GETS GST ORDER WITH INTEREST OF 65.9 MILLION RUPEES, PENALTY OF 870.7 MILLION RUPEES

Source text: ID:nBSE3fV1V2

Further company coverage: UNLB.NS

(([email protected];;))

Nov 13 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABORATORIES SEPT-QUARTER CONSOL PAT 304.9 MILLION RUPEES

• UNICHEM LABORATORIES SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.62 BILLION RUPEES

Source text: ID:nBSE34ycnw

Further company coverage: UNLB.NS

(([email protected];;))

** Shares of Unichem Laboratories UNLB.NS up 3.5% at 681.1 rupees

** Specialty pharmaceutical co enters agreements to purchase all rights in product approvals and goodwill associated with nine abbreviated new drug applications (ANDA) of Bayshore USA for $2.7 million

** Co's U.S. unit to buy U.S. generics formulations marketing/distribution business of Bayshore USA for $10 million

** Stock up 67% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Sept 30 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• APPROVED ENTERING INTO AGREEMENTS WITH BAYSHORE PHARMACEUTICALS LLC

• PURCHASE OF RIGHTS, TITLE, INTEREST IN PRODUCT, GOODWILL ASSOCIATED WITH 9 ANDAS OF BAYSHORE USA

• PURCHASE FOR $2.7 MILLION

• UNIT TO BUY USA GENERICS FORMULATIONS MARKETING/DISTRIBUTION BUSINESS OF BAYSHORE USA

• UNIT'S DEAL FOR $10 MILLION

Source text for Eikon: ID:nBSENh6PT

Further company coverage: UNLB.NS

(([email protected];;))

Sept 23 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABORATORIES - TO CONSIDER CONSOLIDATION OF GENERICS FORMULATIONS BUSINESS IN US MARKET

Source text for Eikon: ID:nBSE9Qs9KG

Further company coverage: UNLB.NS

(([email protected];))

Sept 10 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABORATORIES LTD - USFDA HAS NOW CLASSIFIED INSPECTION AS VOLUNTARY ACTION INDICATED

• UNICHEM LABORATORIES - INSPECTION OF GOA FACILITY CLASSIFIED AS VAI BY USFDA

Source text for Eikon: ID:nBSE7ZQ2Vl

Further company coverage: UNLB.NS

(([email protected];))

Aug 8 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABORATORIES JUNE-QUARTER CONSOL PAT 92.6 MILLION RUPEES

• UNICHEM LABORATORIES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.46 BILLION RUPEES

• UNICHEM LABORATORIES LTD - NAMES SANJAY JAIN AS CFO

Source text for Eikon: [ID:]

Further company coverage: UNLB.NS

(([email protected];))

June 27 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• COURT OF JUSTICE OF EU UPHELD FINE OF EURO 13.96 MILLION ON CO, ITS UNIT NICHE GENERICS

• FINE PERTAINING TO PATENT DISPUTE SETTLEMENT AGREEMENT DONE FOR PERINDOPRIL DRUG MATTER

Further company coverage: UNLB.NS

(([email protected];))

May 31 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• UNICHEM LABORATORIES LTD - SANDIP GHUME RESIGNS AS DEPUTY CHIEF FINANCIAL OFFICER

Source text for Eikon: ID:nBSE55L30S

Further company coverage: UNLB.NS

(([email protected];))

** Shares of Unichem Laboratories UNLB.NS down 2.3% at 555 rupees

** Stock on track to snap three straight sessions of gains

** The pharma co's March-qtr consol loss after tax widens to 1.29 bln rupees ($15.5 mln) from 442.7 mln rupees a year ago

** UNLB incurred a one-time expense of 1.26 bln rupees

** Including session's losses, stock up ~37% YTD

($1 = 83.2410 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

May 22 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• MARCH-QUARTER CONSOL LOSS AFTER TAX 1.29 BILLION RUPEES VERSUS LOSS 442.7 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.32 BILLION RUPEES VERSUS 4.02 BILLION RUPEES

Further company coverage: UNLB.NS

(([email protected];))

** Shares of Unichem Laboratories UNLB.NS surge 17.3% to a record high to 548.7 rupees; last up ~13%

** Pharmaceutical firm reported Dec-qtr profit of 839.9 mln rupees ($10.1 mln) vs yr-ago loss of 639.3 mln rupees; rev from ops rose nearly 44%

** Stock on track for best day since early-April 2023 if gains hold

** More than 1 mln shares change hands by 2:30 p.m. IST, 20.5x the 30-day avg

** Stock fell 2.9% in the reporting quarter, but rose 15.3% in Jan. 2024

($1 = 83.0566 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Jan 11 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• RECEIVED ANDA APPROVAL FOR ITS DOXAZOSIN TABLETS USP, 1 MG, 2 MG, 4 MG AND 8 MG

• RECEIVED ANDA APPROVAL FOR ITS DOXAZOSIN TABLETS FROM USFDA

• PRODUCT WILL BE COMMERCIALIZED FROM UNICHEM'S GOA PLANT

Source text for Eikon: ID:nBSE45sG7p

Further company coverage: UNLB.NS

(([email protected];))

Dec 4 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• SOLD BALANCE STAKE HELD IN OPTIMUS DRUGS TO SEKHMET FOR AGGREGATE CONSIDERATION OF 674.7 MILLION RUPEES

Source text for Eikon: ID:nNSE9yNlY4

Further company coverage: UNLB.NS

(([email protected];))

** IIFL Alternative Research expects nine Indian companies to be added to MSCI India Standard index on Nov. 14

** IIFL expects most inflows into IndusInd Bank INBK.NS and Persistent Systems PERS.NS

** Says Zomato ZOMT.NS, DLF DLF.NS and Hindustan Aeronautics HIAE.NS likely to see biggest rise in weightage

** Says existing index members Reliance Industries RELI.NS, Sun Pharma SUN.NS, Infosys INFY.NS, L&T LART.NS could see outflows and drop in weightage and outflows

** Expects no deletions from MSCI India Standard index

** IIFL also expects around 32 small-cap additions into the MSCI India Small-Cap index

** Sees Unichem Labs UNLB.NS, Precision Camshafts PRCM.NS, Gateway Distriparks GATW.NS among likely additions and Vinati Organics VNTI.NS, Solar Industries SLIN.NS, BHEL BHEL.NS among deletions

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Oct 3 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• RECEIVED A SHOW CAUSE CUM DEMAND NOTICE FROM ASST. COMMISSIONER OF STATE TAX

• SHOW CAUSE CUM DEMAND NOTICE ALLEGING TAX DEMAND OF 27.4 MILLION RUPEES

Further company coverage: UNLB.NS

(([email protected];))

Sept 1 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• SCHEMES OF HDFC MUTUAL FUND RAISE STAKE IN UNICHEM LABORATORIES TO 7.41% FROM 5.34% - EXCHANGE FILING

Source text for Eikon: ID:nBSE6bM2TF

Further company coverage: UNLB.NS

(([email protected];))

Aug 29 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• RECEIVED ANDA APPROVAL FOR ITS PRASUGREL TABLETS FROM USFDA

• TO MARKET A GENERIC VERSION OF EFFIENT

Source text for Eikon: ID:nBSEb3sDzY

Further company coverage: UNLB.NS

(([email protected];))

Aug 2 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• AFTER CCI APPROVAL, CO ACQUIRED ABOUT 33.38% OF PAID UP EQUITY SHARE CAPITAL OF UNICHEM LABORATORIES

• DEAL FOR 9.45 BILLION RUPEES

Source text for Eikon: ID:nBSEVdzbP

Further company coverage: IPCA.NS

(([email protected];;))

July 27 (Reuters) - IPCA Laboratories Ltd IPCA.NS:

• COMPETITION REGULATOR APPROVES ACQUISITION OF UPTO 59.38% STAKE OF UNICHEM LABORATORIES BY IPCA LABORATORIES

Source text for Eikon: [ID:]

Further company coverage: IPCA.NS

(([email protected];))

July 14 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• JUNE-QUARTER CONSOL LOSS AFTER TAX 6.9 MILLION RUPEES VERSUS LOSS 233.7 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.23 BILLION RUPEES VERSUS 3.10 BILLION RUPEES

Source text for Eikon: ID:nBSE9wXvlq

Further company coverage: UNLB.NS

(([email protected];))

June 26 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• RE-APPOINTS PRAKASH A. MODY AS CHAIRMAN, MANAGING DIRECTOR

Source text for Eikon: ID:nBSE9x62x3

Further company coverage: UNLB.NS

(([email protected];))

May 23 (Reuters) - Unichem Laboratories Ltd UNLB.NS:

• MARCH-QUARTER CONSOL LOSS AFTER TAX 442.7 MILLION RUPEES VERSUS PROFIT 714.7 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.02 BILLION RUPEES VERSUS 3.70 BILLION RUPEES

Source text for Eikon: ID:nBSE6rmx22

Further company coverage: UNLB.NS

(([email protected];))

** Shares of IPCA Laboratories Ltd IPCA.NS fall as much as 7.33% to 686.80 rupees, a fresh three-year low

** Stock of the pharma firm lost over 10% on Tuesday after agreeing to buy a 33.38% stake in Unichem Laboratories UNBL.NS for up to 10.34 billion rupees

** Relative strength index of the stock at 21, suggesting it may be oversold

ACQUISITION EXPENSIVE AND EARNINGS DILUTIVE

** Nomura ("neutral", PT of 911 rupees) says IPCA aims to leverage Unichem's development and manufacturing infrastructure but sees near-term negative impact from the acquisition for earnings

** Motilal Oswal ("neutral", PT of 760 rupees) cuts FY24 and FY25 earnings estimates by 11.7% and 5%, respectively, to factor in reduction in income due to use of cash to fund Unichem acquisition

** Prabhudas Lilladher ("hold", PT of 750 rupees) says acquisition cost is expensive and dilutive for earnings

** PhillipCapital ("neutral", PT of 800 rupees) says acquisition is strategic, providing access to U.S. market for IPCA, but will likely mount pressure on margins

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

Adds analyst comment, details

BENGALURU, April 25 (Reuters) - Shares of Ipca Laboratories IPCA.NS fell as much as 9.1% to a near three-year low on Tuesday, after it agreed to buy a 33.38% stake in Unichem Laboratories UNLB.NS for up to 10.34 billion rupees ($126.3 million).

Ipca, which makes paracetamol tablets under the brand name Pacimol, will also launch an open offer to Unichem's shareholders to buy an additional 26% stake for 8.05 billion rupees, according to a regulatory filing on Monday.

The stock posted its biggest intraday loss in over eight months before easing to trade down about 7.36% to 765.70 rupees, as of 10:10 a.m. IST. It was the top loser in India's Nifty pharma index .NIPHARM, which is down 0.46%.

"We believe the acquisition is expensive given increased competition in the U.S. generics oral solids space, rising regulatory risks, and strong efforts needed to turnaround Unichem," Motilal Oswal said in a note.

The brokerage, which retains its "buy" rating on the stock, said it awaits better clarity on measures to be implemented by Ipca to "not only aid U.S. sales but also improve margins of Unichem business over the stipulated time."

The average rating of 21 analysts covering the stock is "hold" and their median target price is 911 rupees, according to Refinitiv data.

($1 = 81.8700 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru; Editing by Sonia Cheema)

(([email protected]; +91 7982114624;))

BENGALURU, April 24 (Reuters) - Indian pharmaceutical firm Ipca Laboratories Ltd IPCA.NS said on Monday it has agreed to buy a 33.38% stake in Unichem Laboratories Ltd UNLB.NS for up to 10.34 billion rupees ($126.26 million).

Ipca, which makes paracetamol tablets under the brand name Pacimol, is also launching an open offer to Unichem's shareholders to buy an additional 26% stake for 8.05 billion rupees, it said in a regulatory filing.

Unichem's core business includes manufacturing branded generic drugs, while Ipca primarily makes active pharmaceutical ingredients or key biologically active elements in a drug that help achieve the desired health effects.

As part of the deal, Unichem's board will approve the appointment of three nominees of Ipca as additional directors, Unichem said in a separate statement.

Shares of Ipca closed 1.7% lower and Unichem's shares settled 3% higher on Monday, ahead of the acquisition announcement.

($1 = 81.8920 Indian rupees)

(Reporting by Biplob Kumar Das in Bengaluru; Editing by Devika Syamnath)

(([email protected]; 9101861583;))